PL3219726T3 - Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty - Google Patents

Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty

Info

Publication number: PL3219726T3
Authority: PL; Poland
Prior art keywords: functional fragments; tnf alpha; alpha antibodies; antibodies; tnf
Prior art date: 2016-03-17

Application number

PL16160907T

Other languages

English (en)

Inventor

Tea Gunde

Sebastian Meyer

Esther Maria FURRER

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2016-03-17

Publication date

2021-07-19

2016-03-17 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2021-07-19 Publication of PL3219726T3 publication Critical patent/PL3219726T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL16160907T 2016-03-17 2016-03-17 Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty PL3219726T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16160907.8A EP3219726B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
PL3219726T3 true PL3219726T3 (pl)	2021-07-19

Family

ID=55542576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL16160907T PL3219726T3 (pl)	2016-03-17	2016-03-17	Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
PL17710748.9T PL3430043T3 (pl)	2016-03-17	2017-03-16	Przeciwciała anty-tnf-alfa i ich funkcjonalne fragmenty

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL17710748.9T PL3430043T3 (pl)	2016-03-17	2017-03-16	Przeciwciała anty-tnf-alfa i ich funkcjonalne fragmenty

Country Status (40)

Country	Link
US (3)	US11459383B2 (pl)
EP (3)	EP3219726B1 (pl)
JP (2)	JP7129398B2 (pl)
KR (2)	KR102470235B1 (pl)
CN (1)	CN109071650B (pl)
AR (1)	AR107917A1 (pl)
AU (2)	AU2017235387B2 (pl)
CA (1)	CA3011784C (pl)
CL (1)	CL2018002649A1 (pl)
CO (1)	CO2018009783A2 (pl)
CR (1)	CR20180448A (pl)
CY (1)	CY1123784T1 (pl)
DK (2)	DK3219726T3 (pl)
EA (1)	EA039760B1 (pl)
ES (3)	ES2836349T3 (pl)
FI (1)	FI3430043T3 (pl)
GE (2)	GEAP202114876A (pl)
HR (2)	HRP20231464T1 (pl)
HU (2)	HUE052773T2 (pl)
IL (2)	IL322669A (pl)
JO (2)	JOP20170064B1 (pl)
LT (2)	LT3219726T (pl)
MA (1)	MA43717B1 (pl)
MD (1)	MD3430043T2 (pl)
MX (1)	MX2018011258A (pl)
MY (1)	MY194041A (pl)
PH (1)	PH12018501907A1 (pl)
PL (2)	PL3219726T3 (pl)
PT (2)	PT3219726T (pl)
RS (2)	RS61374B1 (pl)
SA (1)	SA518400027B1 (pl)
SG (1)	SG11201807062RA (pl)
SI (2)	SI3219726T1 (pl)
SM (2)	SMT202000706T1 (pl)
TN (1)	TN2018000298A1 (pl)
TW (2)	TWI784945B (pl)
UA (1)	UA128715C2 (pl)
UY (1)	UY37157A (pl)
WO (1)	WO2017158092A1 (pl)
ZA (5)	ZA201805919B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017158084A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
PL3219726T3 (pl) *	2016-03-17	2021-07-19	Tillotts Pharma Ag	Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
KR102392746B1 (ko)	2016-03-17	2022-04-29	누맙 이노베이션 아게	항-TNFα-항체 및 이의 기능성 단편
ES2843974T3 (es)	2016-03-17	2021-07-21	Tillotts Pharma Ag	Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos
EP3456738B1 (en) *	2017-09-19	2024-07-17	Tillotts Pharma Ag	Antibody variants
ES2978167T3 (es) *	2017-09-19	2024-09-06	Tillotts Pharma Ag	Variantes de anticuerpos
HUE054261T2 (hu) *	2017-09-19	2021-08-30	Tillotts Pharma Ag	Antitest variánsok
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6258562B1 (en) *	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
PT970126E (pt)	1997-04-14	2001-10-30	Micromet Ag	Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
EP1135498B1 (en)	1998-11-18	2008-01-23	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
EP3260465A1 (en)	2005-06-07	2017-12-27	ESBATech, an Alcon Biomedical Research Unit LLC	Stable and soluble antibodies inhibiting tnf-alpha
ES2677003T3 (es)	2008-06-25	2018-07-27	Esbatech, An Alcon Biomedical Research Unit Llc	Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
CN102076716A (zh)	2008-06-25	2011-05-25	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	抑制TNFα的稳定和可溶的抗体
US8697074B2 (en)	2008-07-10	2014-04-15	Esbatech, An Alcon Biomedical Research Unit Llc	Methods and compositions for enhanced delivery of macromolecules
PH12012501991A1 (en) *	2010-04-07	2017-07-26	Abbvie Inc	Tnf-alpha binding proteins
JP2013536175A (ja) *	2010-07-16	2013-09-19	アブリンクスエン．ヴェー．	修飾された単一ドメイン抗原結合分子及びその使用
SG188987A1 (en) *	2010-09-30	2013-05-31	Chengdu Kanghong Biotechnologies Co Ltd	HUMANIZED ANTI-a ANTIBODY AND ANTIGEN-BINDING FRAGMENT (FAB) THEREOF AND USE OF THE SAME
US10174102B2 (en)	2013-06-26	2019-01-08	Numab Innovation Ag	Antibody frameworks
WO2015065987A1 (en) *	2013-11-01	2015-05-07	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
WO2015144852A1 (en) *	2014-03-26	2015-10-01	Delenex Therapeutics Ag	Binding members to tnf alpha
ES2843974T3 (es)	2016-03-17	2021-07-21	Tillotts Pharma Ag	Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos
WO2017158084A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
PL3219726T3 (pl) *	2016-03-17	2021-07-19	Tillotts Pharma Ag	Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
KR102392746B1 (ko)	2016-03-17	2022-04-29	누맙 이노베이션 아게	항-TNFα-항체 및 이의 기능성 단편
HUE054261T2 (hu) *	2017-09-19	2021-08-30	Tillotts Pharma Ag	Antitest variánsok

2016
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 SM SM20200706T patent/SMT202000706T1/it unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
2017
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 EP EP23192170.1A patent/EP4275745B1/en active Active
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 AU AU2017235387A patent/AU2017235387B2/en active Active
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en not_active Ceased
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active Active
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 GE GEAP202114876A patent/GEAP202114876A/en unknown
- 2017-03-16 DK DK17710748.9T patent/DK3430043T5/da active
- 2017-03-16 ES ES23192170T patent/ES3043897T3/es active Active
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 SM SM20230429T patent/SMT202300429T1/it unknown
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 UA UAA201809317A patent/UA128715C2/uk unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Ceased
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 IL IL322669A patent/IL322669A/en unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
2018
- 2018-08-07 IL IL261031A patent/IL261031B2/en unknown
- 2018-09-04 ZA ZA2018/05919A patent/ZA201805919B/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US12043663B2/en active Active
- 2022-10-03 US US17/958,759 patent/US12209122B2/en active Active
2024
- 2024-09-18 AU AU2024219840A patent/AU2024219840A1/en active Pending

Also Published As

Publication number	Publication date
PT3430043T (pt)	2023-11-23
EP4275745A3 (en)	2023-12-20
EP4275745A2 (en)	2023-11-15
IL261031B2 (en)	2026-01-01
SA518400027B1 (ar)	2022-03-06
ZA202108602B (en)	2022-03-30
ES3043897T3 (en)	2025-11-26
EP3430043B1 (en)	2023-08-30
US20230279091A1 (en)	2023-09-07
EP4275745B1 (en)	2025-07-16
EP3430043A1 (en)	2019-01-23
CO2018009783A2 (es)	2018-09-28
ES2963221T3 (es)	2024-03-26
SMT202000706T1 (it)	2021-01-05
GEP20217307B (en)	2021-10-25
JOP20170064B1 (ar)	2021-08-17
AU2017235387A1 (en)	2018-09-27
MA43717A (fr)	2018-11-28
IL261031B1 (en)	2025-09-01
MY194041A (en)	2022-11-09
SG11201807062RA (en)	2018-09-27
JP7129398B2 (ja)	2022-09-01
ZA201805919B (en)	2024-12-18
EA039760B1 (ru)	2022-03-10
CA3011784A1 (en)	2017-09-21
MA43717B1 (fr)	2023-11-30
LT3219726T (lt)	2021-01-25
MD3430043T2 (ro)	2024-02-29
HRP20210123T1 (hr)	2021-03-05
HUE052773T2 (hu)	2021-05-28
KR102470235B1 (ko)	2022-11-24
TW202311288A (zh)	2023-03-16
US11459383B2 (en)	2022-10-04
RS61374B1 (sr)	2021-02-26
GEAP202114876A (en)	2021-05-13
HRP20231464T1 (hr)	2024-03-01
PT3219726T (pt)	2020-12-15
PH12018501907A1 (en)	2019-06-17
DK3430043T5 (da)	2024-09-23
ES2836349T3 (es)	2021-06-24
IL322669A (en)	2025-10-01
EA201891788A1 (ru)	2019-01-31
MX2018011258A (es)	2019-02-13
KR20220158877A (ko)	2022-12-01
SMT202300429T1 (it)	2024-01-10
BR112018016667A2 (pt)	2019-02-05
ZA202108600B (en)	2022-03-30
JP2022130407A (ja)	2022-09-06
RS64830B1 (sr)	2023-12-29
CN109071650A (zh)	2018-12-21
US12043663B2 (en)	2024-07-23
UY37157A (es)	2017-10-31
AR107917A1 (es)	2018-06-28
US20230272059A1 (en)	2023-08-31
HUE064238T2 (hu)	2024-02-28
SI3219726T1 (sl)	2021-02-26
EP3219726A1 (en)	2017-09-20
CN109071650B (zh)	2022-05-13
CA3011784C (en)	2024-04-23
UA128715C2 (uk)	2024-10-09
LT3430043T (lt)	2023-12-27
US12209122B2 (en)	2025-01-28
WO2017158092A1 (en)	2017-09-21
TWI829444B (zh)	2024-01-11
TWI784945B (zh)	2022-12-01
TW201739766A (zh)	2017-11-16
FI3430043T3 (fi)	2023-11-17
US20210198353A1 (en)	2021-07-01
IL261031A (en)	2018-10-31
NZ745999A (en)	2024-08-30
ZA202108601B (en)	2022-03-30
EP3219726B1 (en)	2020-12-02
CR20180448A (es)	2019-01-25
JP2019512268A (ja)	2019-05-16
ZA202108599B (en)	2022-03-30
PL3430043T3 (pl)	2024-03-11
AU2024219840A1 (en)	2024-10-10
SI3430043T1 (sl)	2024-01-31
DK3430043T3 (da)	2023-11-27
KR20180120149A (ko)	2018-11-05
TN2018000298A1 (en)	2020-01-16
AU2017235387B2 (en)	2024-06-27
JOP20210085A1 (ar)	2023-01-30
DK3219726T3 (da)	2020-12-07
CY1123784T1 (el)	2022-05-27
CL2018002649A1 (es)	2018-11-09

Publication	Publication Date	Title
KR102162129B9 (ko)	2023-02-08	항-갈렉틴-9 항체 및 이의 용도
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
EP3740224A4 (en)	2022-05-04	ANTI-LILRB ANTIBODIES AND THEIR USES
DK3383916T3 (da)	2022-03-28	Anti-CD73-antistoffer og anvendelser deraf
IL250566B2 (en)	2023-03-01	Anti-lag3 antibodies and antigen-binding fragments
LT3274370T (lt)	2020-02-10	Antikūnai prieš ceacam6 ir jų panaudojimas
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
PL3653221T3 (pl)	2022-12-19	Przeciwciała anty-pvrig i sposoby ich zastosowania
PL3219727T3 (pl)	2021-05-17	Przeciwciała anty-TNF alfa i ich funkcjonalne fragmenty
LT3250610T (lt)	2023-09-25	Fcrn antikūnai ir jų panaudojimo būdai
DK3596125T3 (da)	2025-12-22	Anti-PAR2-antistoffer og anvendelser deraf
IL262776A (en)	2018-12-31	Humanized anti-il-1r3 antibodies
LT3532499T (lt)	2021-08-10	Antikūnai prieš il-33 ir jų panaudojimas
EP3904382A4 (en)	2022-07-13	ANTI-IL-23P19 ANTIBODIES AND ITS USES
LT3491025T (lt)	2023-11-27	Fcrn antikūnai ir jų panaudojimo būdai
DK3402821T5 (da)	2024-09-23	Psma-bindende antistof og anvendelser deraf
PL3219726T3 (pl)	2021-07-19	Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
PL3280440T3 (pl)	2023-06-19	Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
IL271398A (en)	2020-01-30	Anti-l1-cam antibodies and uses thereof
IL281297A (en)	2021-04-29	Anti-npr1 antibodies and uses thereof
EP3672987C0 (en)	2025-04-16	ANTI-APELIN ANTIBODIES AND THEIR USES
IL283875A (en)	2021-07-29	Anti-il-27 antibodies and uses thereof
IL258924A (en)	2018-06-28	Humanized anti-dkk2 antibody and uses thereof
EP3585800A4 (en)	2021-06-02	Novel minor histocompatibility antigens and uses thereof
IL279790A (en)	2021-03-01	Anti-l1cam antibodies and uses thereof